With launches on the way in the US and EU, MC2 turns attention to the rest of its pipeline
Over the next 12 months, MC2 Therapeutics will start three new clinical studies with the follow-up drugs to Wynzora, which will soon be launched in the US and Europe.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY CATHERINE BRETT
The launch of psoriasis drug Wyzora alongside Epi Health marks the beginning of a new era for MC2 Therapeutics.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg&w=384&q=75)
